Here is access to the latest Wyeth UK press releases, news topics and media contacts
15th November 2007
Established depression medication, Efexor* XL (venlafaxine) adds to evidence base with the approval of social phobia licence
5th October 2007
Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
15 August 2007
WYETH WINS WORLD AWARD FOR INVESTMENT IN SCOTLAND
17 July 2007
New investment at Wyeth Pharmaceuticals’ Havant site
5 June 2007
WYETH ANNOUNCES THE APPOINTMENT OF A NEW CORPORATE AFFAIRS DIRECTOR
25 April 2007
Amendment to NICE clinical guidelines on depression and anxiety
16 April 2007
Prevenar* licence extended to include indications for pneumonia and otitis media
9 January 2007
UK Has the Fifth Highest MRSA Rate in Europe
4 September 2006
Havant supplies life-saving childhood vaccine
28 August 2006
Prevenar* , Wyeth’s pneumococcal conjugate vaccine, added to UK’s routine childhood immunisation programme from Monday, 4th September
20 July 2006
Much needed new antibiotic in fight against ‘superbugs’ now available in the UK
12 July 2006
Introduction of Prevenar into the UK childhood immunisation programme
10 July 2006
Scotland at the forefront in treatment of hospital infections
3 April 2006
Wyeth Pharmaceuticals Announces Scottish Collaboration to Enhance Translational Medicine Research.
>> click for media pack
2 March 2006
Re-organisation of Wyeth's Havant site.
1 December 2005
Wyeth Receives Honours at the 2005 Scrip Awards.
News Topics
Wyeth continues to support relief efforts with International Health Partners (IHP).
Click here for Wyeth media contacts in the UK
Please note: the press releases below are from and will link to our US website, www.wyeth.com.
November 8, 2007
Wyeth Scientists Receive 2007 Thomas Alva Edison Patent Award
November 8, 2007
Wyeth to Present at the Credit Suisse First Boston Healthcare Conference
October 25, 2007
FDA Accepts Wyeth's Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
October 18, 2007
Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months
October 15, 2007
Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
October 15, 2007
Wyeth and Progenics to Initiate Phase 2 Trials of Oral Methylnaltrexone in Chronic-pain Setting
October 8, 2007
Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene / Conjugated Estrogens
October 5, 2007
Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease
September 27, 2007
Wyeth Announces Election of Bernard Poussot as CEO of Company Effective January 1, 2008
September 27, 2007
Wyeth Announces the Election of Robert M. Amen to Its Board of Directors
September 27, 2007
Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
September 25, 2007
Wyeth Selected for 10th Consecutive Year as One of Working Mother Magazine's 100 Best Companies for Working Mothers
September 24, 2007
Wyeth's Pearl River, N.Y. Facility Celebrates 100 Years of Achievements in Health Care
September 20, 2007
European Committee Issues Positive Opinion on Wyeth's TORISEL for Advanced Renal Cell Carcinoma
September 19, 2007
Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
September 18, 2007
Wyeth to Present at the UBS Global Life Sciences Conference
September 17, 2007
Kylin Therapeutics signs collaboration with Fort Dodge Animal Health, a Division of Wyeth
September 12, 2007
Wyeth and Progenics Initiate New Clinical Studies to Investigate Additional Patient Populations for Methylnaltrexone
September 7, 2007
Wyeth Sets Webcast And Conference Call For 2007 Third Quarter Earnings
September 5, 2007
Wyeth to Present at the Bear Stearns 20th Annual Healthcare Conference
September 5, 2007
Wyeth Pharmaceuticals Announces Organizational Changes
August 20, 2007
Four Wyeth Researchers Honored by American Chemical Society for Pioneering Contributions to Medicinal Chemistry
August 20, 2007
Wyeth Receives Approval from European Medicines Agency for New BeneFIX Features
August 13, 2007
EPA Approves Fort Dodge Animal Health's ProMeris for Dogs
August 10, 2007
Wyeth Pharmaceuticals and Solvay Pharmaceuticals, Inc. Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
August 9, 2007
Wyeth Rated Best in Pharmaceutical Industry on The Wall Street Journal Patent Scorecard
20 July 2006
Wyeth Reports Earnings Results for the 2006 Second Quarter and First Half
12 July 2006
Wyeth Provides 2006 Mid-Year Business Update
28 June 2006
Dr. George Ellestad Receives ACS Medicinal Chemistry Award
24 May 2006
Seventh Amendment to Nationwide Diet Drug Settlement Receives Final Judicial Approval
23 May 2006
New Study Reports Venlafaxine Extended Release May Help Adult Patients Prevent New Episodes of Depression for Up to Two Years
18 May 2006
Wyeth Launches New Customer-centric Web Site
16 May 2006
Wyeth Announces New Head of Corporate Diversity Effort
12 May 2006
Wyeth to Present at the Bank of America Health Care Conference
2 May 2006
New Broad-spectrum Antibiotic Tygacil* (tigecycline) Receives Approval for Use in Europe Today
Press releases contained on this page are intended as reference information. The information contained in each press release was accurate at the time of posting on this website, and Wyeth assumes no obligation for updating the information to reflect subsequent developments.